share_log

Wedbush Initiates Coverage On ARS Pharmaceuticals With Outperform Rating, Announces Price Target of $10

Benzinga Real-time News ·  Jan 31, 2023 07:15

Wedbush analyst Andreas Argyrides initiates coverage on ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform rating and announces Price Target of $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment